Gastroesophageal Varices in Cavernoma

Study Overview
=================
Brief Summary
-----------------
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.

Official Title
-----------------
Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma

Conditions
-----------------
Gastroesophageal Varices, Myeloproliferative Neoplasm, Portal Caver Cavernoma, Portal Hypertension

Intervention / Treatment
-----------------
* Diagnostic Test: JAK2 mutation test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female patients aged 18-75 diagnosed as portal hypertension and portal cavernoma by contrast-enhanced computed tomography underwent JAK2 mutation test Exclusion Criteria: combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease. other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| JAK2 mutation Group<br>Patients with portal caver cavernoma and gastroesophageal varices and JAK2 Mutation. | Diagnostic Test: JAK2 mutation test<br>* Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test<br>|
| Portal caver cavernoma Group<br>Patients with portal caver cavernoma and gastroesophageal varices without JAK2 Mutation. | Diagnostic Test: JAK2 mutation test<br>* Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| History of variceal bleeding | Have a history of the occurrence of gastroesophageal variceal bleeding | 1 day (the same time as diagnosis) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1-year death rate | 1-year death rate | 1 year | 
| Complications of portal hypertension | The concurrence of complications of portal hypertension (ascites, infections, variceal bleeding, et al) | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
portal hypertension, gastroesophageal varices, jak2 mutation, myeloproliferative Neoplasm, portal caver cavernoma